Veru INC 8-K filings

Veru Inc. announced fiscal 2026 third quarter financial results, highlighting full enrollment in its Phase 2b PLATEAU clinical trial for enobosarm and semaglutide combination therapy for weight loss, alongside a significant patent allowance.

Veru Inc. has entered into a clinical supply agreement with Novo Nordisk A/S to evaluate enobosarm in combination with Wegovy for obesity in older adults.

Veru Inc. announced fiscal 2026 second quarter financial results, highlighting reduced net loss and progress in its Phase 2b PLATEAU clinical trial for enobosarm.

Veru Inc. shareholders approved an amendment to its 2018 Equity Incentive Plan, significantly increasing the number of shares available for issuance and individual award limits, alongside electing directors and ratifying auditors.

Veru Inc. announced its fiscal 2026 first quarter financial results and provided updates on its enobosarm clinical program for obesity, including plans to initiate the Phase 2b PLATEAU trial.

Veru Inc. announced fiscal year 2025 financial results and significant clinical progress for its enobosarm obesity program, including FDA regulatory clarity and plans for a new Phase 2b study.

Veru Inc. announced the pricing of a public offering of common stock and warrants, expecting to raise $25.2 million in gross proceeds to advance its enobosarm clinical program.

Veru Inc. resolves $8.8 million defaulted promissory notes with Onconetix, receiving $6.3 million cash and equity instruments.

Veru Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a previous listing deficiency.

Veru Inc. will implement a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective August 8, 2025.

Veru Inc. announced positive fiscal 2025 third-quarter financial results and significant clinical progress for its enobosarm program, highlighting its potential in chronic weight loss management.

VERU Inc. shareholders approved a proposal to amend the company's Articles of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20, along with an adjournment proposal, at a special meeting held on July 25, 2025.

Veru Inc. reports positive topline results from its Phase 2b QUALITY clinical study and provides updates on its clinical development programs, along with its fiscal 2025 second quarter financial results.

Veru Inc. shareholders approved an amendment to the 2018 Equity Incentive Plan, increasing the number of shares authorized for issuance from 18,500,000 to 26,000,000 at the Annual Meeting held on March 13, 2025.

Veru Inc. receives an extension from Nasdaq until August 25, 2025, to regain compliance with the minimum bid price requirement of $1.00 per share.

Veru Inc. reports positive topline results from its Phase 2b QUALITY study of enobosarm + semaglutide, demonstrating preservation of lean mass, greater fat loss, and improved physical function, while also announcing the sale of its FC2 Female Condom business and providing a financial update for the first quarter of fiscal year 2025.

Veru Inc. has divested its FC2 female condom business for $18 million to concentrate on its late-stage clinical drug pipeline.

Veru Inc. has amended its forbearance agreement with Onconetix, Inc., extending the maturity dates of two promissory notes and modifying payment terms to facilitate repayment.

Veru Inc. has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, as its stock price has been below $1.00 for 30 consecutive days.

Veru Inc. has terminated its Open Market Sales Agreement with Jefferies LLC, effective September 3, 2024, halting further sales of common stock under the agreement.

Veru Inc. has completed enrollment for its Phase 2b clinical trial of enobosarm for obesity and reported its third quarter fiscal 2024 financial results.

Veru Inc. has increased its board size from six to seven directors and appointed Loren Mark Katzovitz to fill the new position.

Veru Inc. successfully elected all nominated directors at its reconvened 2024 Annual Meeting of Shareholders on June 27, 2024.

Veru Inc. adjourned its 2024 Annual Meeting of Shareholders due to insufficient shareholder representation to meet the required quorum.

Veru Inc. has dismissed RSM US LLP as its independent auditor and appointed Cherry Bekaert LLP, effective May 21, 2024.

Veru Inc. reported its fiscal 2024 second quarter financial results and provided an update on the progress of its enobosarm clinical program for high quality weight loss.

Veru Inc. has agreed to a forbearance agreement with Onconetix, allowing the latter more time to repay $10 million in debt, while setting new payment terms.

Veru Inc. has received notification from Nasdaq confirming they have regained compliance with listing standards after their stock price rose above $1.00.

Veru Inc. received a notification from Nasdaq regarding non-compliance with listing rules due to a delay in filing its quarterly report.

Veru Inc. announced it will restate prior financial statements due to errors in overestimating research and development expenses, which impacts the company's cash runway.